Literature DB >> 2760662

The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy.

C S Landefeld1, P A Anderson, L T Goodnough, T W Moir, D L Hom, M W Rosenblatt, L Goldman.   

Abstract

Reports of bleeding complications of medical therapy should be based on valid methods of classification, but the reproducibility of existing methods has not been tested. Therefore, we prospectively studied three methods to classify the severity of bleeding: a purely subjective implicit method, a previously published explicit method using brief criteria, and the bleeding severity index, which is a new explicit method using detailed criteria about the amount, rate, and consequences of bleeding. Three physicians independently reviewed abstracts of 168 patients treated with anticoagulants. The proportion of cases classified as major bleeding varied widely when the implicit method was used (2, 14 and 39%), less when the old explicit method was used (28, 40 and 47%), and not at all when the new bleeding severity index was used (20, 20 and 20%). Intraobserver agreement was excellent for both explicit methods (kappa greater than or equal to 0.95). However, interobserver agreement was better for the bleeding severity index (kappa = 0.87) than for the old explicit method (kappa = 0.69) or the implicit method (kappa = 0.39). We conclude that the classification of bleeding complications of medical therapy depends on the method used. In comparison to older methods, the bleeding severity index is highly reproducible and should be tested more widely to determine whether it can be applied to the burgeoning clinical research in anticoagulation and thrombolysis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2760662     DOI: 10.1016/0895-4356(89)90066-8

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  10 in total

1.  Trans-radial versus trans-femoral access in patients with end-stage liver disease undergoing cardiac catheterization.

Authors:  Kent Feng; Vipul Gupta; Enrique Terrazas; Yerem Yeghiazarians; Thomas Ports; Gabriel Gregoratos; Mehdi Tavakol; John Paul Roberts; Andrew Boyle
Journal:  Am J Cardiovasc Dis       Date:  2014-10-11

2.  Warfarin in atrial fibrillation patients with moderate chronic kidney disease.

Authors:  Robert G Hart; Lesly A Pearce; Richard W Asinger; Charles A Herzog
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 8.237

3.  Patient self-management of warfarin therapy: pragmatic feasibility study in Canadian primary care.

Authors:  Brian E Grunau; Matthew O Wiens; Kenneth K Harder
Journal:  Can Fam Physician       Date:  2011-08       Impact factor: 3.275

4.  Risk of major hemorrhage for outpatients treated with warfarin.

Authors:  D A McMahan; D M Smith; M A Carey; X H Zhou
Journal:  J Gen Intern Med       Date:  1998-05       Impact factor: 5.128

5.  Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation.

Authors:  Mark L Wess; Daniel P Schauer; Joseph A Johnston; Charles J Moomaw; David E Brewer; E Francis Cook; Mark H Eckman
Journal:  J Gen Intern Med       Date:  2008-04       Impact factor: 5.128

6.  Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients.

Authors:  Jos P J Wester; Fred J L M Haas; Douwe H Biesma; J A Leusink; Gerda Veth
Journal:  Intensive Care Med       Date:  2004-05-20       Impact factor: 17.440

Review 7.  Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.

Authors:  Jean-Pierre Bassand
Journal:  Europace       Date:  2012-03       Impact factor: 5.214

8.  Cohort study of Anticoagulation Self-Monitoring (CASM): a prospective study of its effectiveness in the community.

Authors:  Alison Ward; Alice Tompson; David Fitzmaurice; Stephen Sutton; Rafael Perera; Carl Heneghan
Journal:  Br J Gen Pract       Date:  2015-06-15       Impact factor: 5.386

9.  Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.

Authors:  Tanja A Treschan; Maximilian S Schaefer; Johann Geib; Astrid Bahlmann; Tobias Brezina; Patrick Werner; Elisabeth Golla; Andreas Greinacher; Benedikt Pannen; Detlef Kindgen-Milles; Peter Kienbaum; Martin Beiderlinden
Journal:  Crit Care       Date:  2014-10-25       Impact factor: 9.097

Review 10.  Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies.

Authors:  Neil S Roskell; Miny Samuel; Herbert Noack; Brigitta U Monz
Journal:  Europace       Date:  2013-02-13       Impact factor: 5.214

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.